CoChat
Sign Up
Cited by 138Chemotherapy-induced cardiotoxicity and mitigationCancer Immunotherapy and BiomarkersAtherosclerosis and Cardiovascular Diseases

Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies

Open access
Baik, Alan H., Oluwole, Olalekan O., Johnson, Douglas B., Shah, Nina, Salem, Joe-Elie, Tsai, Katy K., Moslehi, Javid J.·2021·Circulation Research
DOI 10.1161/circresaha.120.315894PMC PMC8159878
Open this paper in CoChat — free accountOpen PDF

Abstract

Immune-based therapies have revolutionized cancer treatments. Cardiovascular sequelae from these treatments, however, have emerged as critical complications, representing new challenges in cardio-oncology. Immune therapies include a broad range of novel drugs, from antibodies and other biologics, including immune checkpoint inhibitors and bispecific T-cell engagers, to cell-based therapies, such as chimeric-antigen receptor T-cell therapies. The recognition of immunotherapy-associated cardiovascular side effects has also catapulted new research questions revolving around the interactions between the immune and cardiovascular systems, and the signaling cascades affected by T cell activation, cytokine release, and immune system dysregulation. Here, we review the specific mechanisms of immune activation from immunotherapies and the resulting cardiovascular toxicities associated with immune activation and excess cytokine production.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circresaha.120.315894

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ICI myocarditis has a fatality rate of up to 50%.

    “ICI myocarditis has a high fatality rate of up to 50%.”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [180]

    The Immune Checkpoint Inhibitors section describes ICI-associated myocarditis as having a high fatality rate, but gives the rate as 39.7%, not up to 50%. The cited review supports the severity of the claim but not its stated figure. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

  • ICI myocarditis occurs in less than 1% of patients.

    “Despite occurring in <1% of patients”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [180]

    The Immune Checkpoint Inhibitors section describes ICI-associated myocarditis as occurring about 1% of the time, with incidence estimates of 0.27%–1.14%. This supports its rarity, but the cited range extends above 1%, so the source does not establish a strict incidence below 1%. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 137

  1. [1]Haslam A, Gill J, and Prasad V, “ Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs,” JAMA Netw Open, vol. 3, no. 3, p. e200423, 3. 2020, doi: 10.1001/jamanetworkopen.2020.0423. 32150268 PMC7063495 · DOI · Paper page
  2. [2]June CH and Sadelain M, “ Chimeric Antigen Receptor Therapy,” N. Engl. J. Med, vol. 379, no. 1, pp. 64– 73, 05 2018, doi: 10.1056/NEJMra1706169. 29972754 PMC7433347 · DOI
  3. [3]Schildberg FA, Klein SR, Freeman GJ, and Sharpe AH, “ Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family,” Immunity, vol. 44, no. 5, pp. 955– 972, 17 2016, doi: 10.1016/j.immuni.2016.05.002. 27192563 PMC4905708 · DOI
  4. [4]Wei SC, Duffy CR, and Allison JP, “ Fundamental Mechanisms of Immune Checkpoint Blockade Therapy,” Cancer Discov, vol. 8, no. 9, pp. 1069– 1086, 2018, doi: 10.1158/2159-8290.CD-18-0367. 30115704 · DOI · Paper page
  5. [6]Bluestone JA and Anderson M, “ Tolerance in the Age of Immunotherapy,” N. Engl. J. Med, vol. 383, no. 12, pp. 1156– 1166, 17 2020, doi: 10.1056/NEJMra1911109. 32937048 PMC7534289 · DOI
  6. [7]Krummel MF and Allison JP, “ CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells,” J. Exp. Med, vol. 183, no. 6, pp. 2533– 2540, 6. 1996, doi: 10.1084/jem.183.6.2533. 8676074 PMC2192613 · DOI
  7. [8]Walunas TL, “ CTLA-4 can function as a negative regulator of T cell activation,” Immunity, vol. 1, no. 5, pp. 405– 413, 8. 1994, doi: 10.1016/1074-7613(94)90071-x. 7882171 · DOI · Paper page
  8. [9]Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, and Sharpe AH, “ Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4,” Immunity, vol. 3, no. 5, pp. 541– 547, 11. 1995, doi: 10.1016/1074-7613(95)90125-6. 7584144 · DOI · Paper page
  9. [11]Ribas A and Wolchok JD, “ Cancer immunotherapy using checkpoint blockade,” Science, vol. 359, no. 6382, pp. 1350– 1355, 23 2018, doi: 10.1126/science.aar4060. 29567705 PMC7391259 · DOI · Paper page
  10. [12]Hodi FS, “ Improved survival with ipilimumab in patients with metastatic melanoma,” N. Engl. J. Med, vol. 363, no. 8, pp. 711– 723, 8. 2010, doi: 10.1056/NEJMoa1003466. 20525992 PMC3549297 · DOI · Paper page
  11. [13]Weinmann SC and Pisetsky DS, “ Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors,” Rheumatology (Oxford), vol. 58, no. Suppl 7, pp. vii59– vii67, 01 2019, doi: 10.1093/rheumatology/kez308. 31816080 PMC6900913 · DOI
  12. [14]Andrews LP, Yano H, and Vignali DAA, “ Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups,” Nat. Immunol, vol. 20, no. 11, pp. 1425– 1434, 2019, doi: 10.1038/s41590-019-0512-0. 31611702 · DOI
  13. [16]Johnson DB, Chandra S, and Sosman JA, “ Immune Checkpoint Inhibitor Toxicity in 2018,” JAMA, vol. 320, no. 16, pp. 1702– 1703, 23 2018, doi: 10.1001/jama.2018.13995. 30286224 · DOI
  14. [17]Wang DY, “ Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis,” JAMA Oncol, vol. 4, no. 12, pp. 1721– 1728, 01 2018, doi: 10.1001/jamaoncol.2018.3923. 30242316 PMC6440712 · DOI · Paper page
  15. [18]Hu J-R, “ Cardiovascular toxicities associated with immune checkpoint inhibitors,” Cardiovasc. Res, vol. 115, no. 5, pp. 854– 868, 15 2019, doi: 10.1093/cvr/cvz026. 30715219 PMC6452314 · DOI · Paper page
  16. [19]Salem J-E, “ Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study,” Lancet Oncol, vol. 19, no. 12, pp. 1579– 1589, 2018, doi: 10.1016/S1470-2045(18)30608-9. 30442497 PMC6287923 · DOI · Paper page
  17. [20]Mahmood SS, “ Myocarditis in Patients Treated With Immune Checkpoint Inhibitors,” J. Am. Coll. Cardiol, vol. 71, no. 16, pp. 1755– 1764, 24 2018, doi: 10.1016/j.jacc.2018.02.037. 29567210 PMC6196725 · DOI · Paper page
  18. [21]Geraud A, “ Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance,” Annual Review of Pharmacology and Toxicology, 9. 2020, doi: 10.1146/annurev-pharmtox-022820-093805. 32871087 · DOI
  19. [22]Salem J-E, “ Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis,” N Engl J Med, vol. 380, no. 24, pp. 2377– 2379, 6. 2019, doi: 10.1056/NEJMc1901677. 31189043 · DOI · Paper page
  20. [23]Johnson DB, “ Fulminant Myocarditis with Combination Immune Checkpoint Blockade,” N. Engl. J. Med, vol. 375, no. 18, pp. 1749– 1755, 11. 2016, doi: 10.1056/NEJMoa1609214. 27806233 PMC5247797 · DOI · Paper page
  21. [24]Wei SC, “ A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention,” Cancer Discov, p. CD-20–0856, 11. 2020, doi: 10.1158/2159-8290.CD-20-0856. PMC8041233 33257470 · DOI · Paper page
  22. [25]Anquetil C, “ Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution,” Circulation, vol. 138, no. 7, pp. 743– 745, 14 2018, doi: 10.1161/CIRCULATIONAHA.118.035898. 30359135 · DOI
  23. [26]Johnson DB, “ Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study,” Journal for Immunotherapy of Cancer, vol. 7, no. 1, p. 134, 22 2019, doi: 10.1186/s40425-019-0617-x. 31118078 PMC6530194 · DOI
  24. [27]Allenbach Y, “ Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities,” Autoimmunity Reviews, vol. 19, no. 8, p. 102586, 8. 2020, doi: 10.1016/j.autrev.2020.102586. 32535094 · DOI
  25. [28]Drobni ZD, “ Association Between Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque,” Circulation, 10. 2020, doi: 10.1161/CIRCULATIONAHA.120.049981. PMC7736526 33003973 · DOI
  26. [29]Waliany S, “ Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure,” Annu. Rev. Pharmacol. Toxicol, 8. 2020, doi: 10.1146/annurev-pharmtox-010919-023451. 32776859 · DOI
  27. [30]Gormley NJ and Pazdur R, “ Immunotherapy Combinations in Multiple Myeloma — Known Unknowns,” N Engl J Med, vol. 379, no. 19, pp. 1791– 1795, 11. 2018, doi: 10.1056/NEJMp1803602. 30403935 · DOI
  28. [31]Grabie N, Lichtman AH, and Padera R, “ T cell checkpoint regulators in the heart,” Cardiovasc. Res, vol. 115, no. 5, pp. 869– 877, 15 2019, doi: 10.1093/cvr/cvz025. 30721928 PMC6452292 · DOI
  29. [32]Lim SY, “ Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy,” Clin Cancer Res, vol. 25, no. 5, pp. 1557– 1563, 3. 2019, doi: 10.1158/1078-0432.CCR-18-2795. 30409824 · DOI · Paper page
  30. [33]Tarhini AA, “ Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma,” J Immunother Cancer, vol. 3, p. 39, 2015, doi: 10.1186/s40425-015-0081-1. 26380086 PMC4570556 · DOI · Paper page
  31. [35]Rodig N, “ Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis,” Eur. J. Immunol, vol. 33, no. 11, pp. 3117– 3126, 11. 2003, doi: 10.1002/eji.200324270. 14579280 · DOI
  32. [36]Baban B, Liu JY, Qin X, Weintraub NL, and Mozaffari MS, “ Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153,” PLoS ONE, vol. 10, no. 4, p. e0124059, 2015, doi: 10.1371/journal.pone.0124059. 25902191 PMC4406739 · DOI
  33. [37]Grabie N, “ Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart,” Circulation, vol. 116, no. 18, pp. 2062– 2071, 10. 2007, doi: 10.1161/CIRCULATIONAHA.107.709360. 17938288 · DOI
  34. [38]Altan M, “ Immune Checkpoint Inhibitor–Associated Pericarditis,” Journal of Thoracic Oncology, vol. 14, no. 6, pp. 1102– 1108, 6. 2019, doi: 10.1016/j.jtho.2019.02.026. 30851443 PMC6617516 · DOI
  35. [41]Slaney CY, Wang P, Darcy PK, and Kershaw MH, “ CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment,” Cancer Discov, vol. 8, no. 8, pp. 924– 934, 2018, doi: 10.1158/2159-8290.CD-18-0297. 30012854 · DOI
  36. [42]Sedykh S, Prinz V, Buneva V, and Nevinsky G, “ Bispecific antibodies: design, therapy, perspectives,” DDDT, vol. Volume 12, pp. 195– 208, 1. 2018, doi: 10.2147/DDDT.S151282. 29403265 PMC5784585 · DOI
  37. [43]Pipe SW, “ Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study,” Lancet Haematol, vol. 6, no. 6, pp. e295– e305, 6. 2019, doi: 10.1016/S2352-3026(19)30054-7. 31003963 · DOI
  38. [44]Bargou R, “ Tumor regression in cancer patients by very low doses of a T cell-engaging antibody,” Science, vol. 321, no. 5891, pp. 974– 977, 8. 2008, doi: 10.1126/science.1158545. 18703743 · DOI · Paper page
  39. [45]Kantarjian H, “ Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia,” N Engl J Med, vol. 376, no. 9, pp. 836– 847, 3. 2017, doi: 10.1056/NEJMoa1609783. 28249141 PMC5881572 · DOI
  40. [46]von Stackelberg A, “ Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia,” J. Clin. Oncol, vol. 34, no. 36, pp. 4381– 4389, 20 2016, doi: 10.1200/JCO.2016.67.3301. 27998223 · DOI
  41. [47]Przepiorka D, “ FDA Approval: Blinatumomab,” Clin. Cancer Res, vol. 21, no. 18, pp. 4035– 4039, 9. 2015, doi: 10.1158/1078-0432.CCR-15-0612. 26374073 · DOI
  42. [48]Gökbuget N, “ Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia,” Blood, vol. 131, no. 14, pp. 1522– 1531, 05 2018, doi: 10.1182/blood-2017-08-798322. 29358182 PMC6027091 · DOI
  43. [49]Topp MS, “ Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study,” The Lancet Oncology, vol. 16, no. 1, pp. 57– 66, 1. 2015, doi: 10.1016/S1470-2045(14)71170-2. 25524800 · DOI · Paper page
  44. [50]Kalos M, “ T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia,” Science Translational Medicine, vol. 3, no. 95, pp. 95ra73– 95ra73, 8. 2011, doi: 10.1126/scitranslmed.3002842. PMC3393096 21832238 · DOI
  45. [51]Rafiq S, Hackett CS, and Brentjens RJ, “ Engineering strategies to overcome the current roadblocks in CAR T cell therapy,” Nat Rev Clin Oncol, vol. 17, no. 3, pp. 147– 167, 3. 2020, doi: 10.1038/s41571-019-0297-y. 31848460 PMC7223338 · DOI
  46. [54]Locke FL, “ Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial,” Lancet Oncol, vol. 20, no. 1, pp. 31– 42, 2019, doi: 10.1016/S1470-2045(18)30864-7. 30518502 PMC6733402 · DOI · Paper page
  47. [56]Raje N, “ Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma,” N. Engl. J. Med, vol. 380, no. 18, pp. 1726– 1737, 02 2019, doi: 10.1056/NEJMoa1817226. 31042825 PMC8202968 · DOI · Paper page
  48. [57]Yeku O, Li X, and Brentjens RJ, “ Adoptive T-Cell Therapy for Solid Tumors,” Am Soc Clin Oncol Educ Book, vol. 37, pp. 193– 204, 2017, doi: 10.1200/EDBK_180328. 28561728 PMC5549627 · DOI
  49. [58]Ganatra S, “ Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart,” Journal of the American College of Cardiology, vol. 74, no. 25, pp. 3153– 3163, 12. 2019, doi: 10.1016/j.jacc.2019.10.049. 31856973 PMC8211027 · DOI
  50. [59]Gutierrez C, “ Management of the Critically Ill Adult Chimeric Antigen Receptor-T Cell Therapy Patient: A Critical Care Perspective,” Crit. Care Med, vol. 46, no. 9, pp. 1402– 1410, 2018, doi: 10.1097/CCM.0000000000003258. 29939878 PMC9503150 · DOI
  51. [60]Alvi RM, “ Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T),” Journal of the American College of Cardiology, vol. 74, no. 25, pp. 3099– 3108, 12. 2019, doi: 10.1016/j.jacc.2019.10.038. 31856966 PMC6938409 · DOI
  52. [61]Lefebvre B, Kang Y, Smith AM, Frey NV, Carver JR, and Scherrer-Crosbie M, “ Cardiovascular Effects of CAR T Cell Therapy: A Retrospective Study,” JACC CardioOncol, vol. 2, no. 2, pp. 193– 203, 6. 2020, doi: 10.1016/j.jaccao.2020.04.012. 32776016 PMC7413146 · DOI
  53. [62]Salem J-E, Ederhy S, Lebrun-Vignes B, and Moslehi JJ, “ Cardiac Events Associated With Chimeric Antigen Receptor T-Cells (CAR-T): A VigiBase Perspective,” J. Am. Coll. Cardiol, vol. 75, no. 19, pp. 2521– 2523, 5 2020, doi: 10.1016/j.jacc.2020.02.070. 32408984 · DOI
  54. [63]Linette GP, “ Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma,” Blood, vol. 122, no. 6, pp. 863– 871, 8. 2013, doi: 10.1182/blood-2013-03-490565. 23770775 PMC3743463 · DOI
  55. [64]Herman DS, “ Truncations of Titin Causing Dilated Cardiomyopathy,” N Engl J Med, vol. 366, no. 7, pp. 619– 628, 2. 2012, doi: 10.1056/NEJMoa1110186. 22335739 PMC3660031 · DOI · Paper page
  56. [66]Apel A, “ Safety and efficacy of blinatumomab: a real world data,” Ann Hematol, vol. 99, no. 4, pp. 835– 838, 4. 2020, doi: 10.1007/s00277-019-03854-0. 32076826 · DOI
  57. [67]Nastoupil LJ, “ Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium,” J. Clin. Oncol, p. JCO1902104, 5 2020, doi: 10.1200/JCO.19.02104. PMC7499611 32401634 · DOI · Paper page
  58. [68]Oluwole OO and Davila ML, “ At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies,” J. Leukoc. Biol, vol. 100, no. 6, pp. 1265– 1272, 2016, doi: 10.1189/jlb.5BT1115-524R. 27354412 PMC12039969 · DOI
  59. [69]Ceschi A, Noseda R, Palin K, and Verhamme K, “ Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database,” Front. Pharmacol, vol. 11, p. 557, 5 2020, doi: 10.3389/fphar.2020.00557. 32425791 PMC7212758 · DOI
  60. [71]Topp MS, “ Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival,” JCO, vol. 29, no. 18, pp. 2493– 2498, 6. 2011, doi: 10.1200/JCO.2010.32.7270. 21576633 · DOI
  61. [72]Rosenberg SA, “ A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone,” N. Engl. J. Med, vol. 316, no. 15, pp. 889– 897, 4. 1987, doi: 10.1056/NEJM198704093161501. 3493432 · DOI
  62. [73]Ferrara JL, Abhyankar S, and Gilliland DG, “ Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1,” Transplant. Proc, vol. 25, no. 1 Pt 2, pp. 1216– 1217, 2. 1993. 8442093
  63. [74]Parker KR, “ Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies,” Cell, 9. 2020, doi: 10.1016/j.cell.2020.08.022. PMC7640763 32961131 · DOI
  64. [75]Hunter BD and Jacobson CA, “ CAR T-cell associated neurotoxicity: Mechanisms, clinicopathologic correlates, and future directions,” J. Natl. Cancer Inst, 2. 2019, doi: 10.1093/jnci/djz017. 30753567 · DOI
  65. [76]Klinger M, “ Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab,” Blood, vol. 119, no. 26, pp. 6226– 6233, 6. 2012, doi: 10.1182/blood-2012-01-400515. 22592608 · DOI
  66. [77]Neelapu SS, “ Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1,” Blood, vol. 128, no. 22, p. LBA-6-LBA-6, 12. 2016, doi: 10.1182/blood.V128.22.LBA-6.LBA-6. · DOI
  67. [78]Norelli M, “ Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells,” Nat. Med, vol. 24, no. 6, pp. 739– 748, 2018, doi: 10.1038/s41591-018-0036-4. 29808007 · DOI · Paper page
  68. [79]Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, and Sadelain M, “ CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade,” Nat Med, vol. 24, no. 6, pp. 731– 738, 6. 2018, doi: 10.1038/s41591-018-0041-7. 29808005 PMC6410714 · DOI · Paper page
  69. [80]Rose-John S, “ Interleukin-6 Family Cytokines,” Cold Spring Harb Perspect Biol, vol. 10, no. 2, 01 2018, doi: 10.1101/cshperspect.a028415. PMC5793756 28620096 · DOI
  70. [81]Tanaka T, Narazaki M, and Kishimoto T, “ Immunotherapeutic implications of IL-6 blockade for cytokine storm,” Immunotherapy, vol. 8, no. 8, pp. 959– 970, 2016, doi: 10.2217/imt-2016-0020. 27381687 · DOI
  71. [82]Nägele V, “ Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL,” Experimental Hematology & Oncology, vol. 6, p. 14, 2017, doi: 10.1186/s40164-017-0074-5. 28533941 PMC5437652 · DOI
  72. [83]Ogura H, “ Interleukin-17 Promotes Autoimmunity by Triggering a Positive-Feedback Loop via Interleukin-6 Induction,” Immunity, vol. 29, no. 4, pp. 628– 636, 10. 2008, doi: 10.1016/j.immuni.2008.07.018. 18848474 · DOI · Paper page
  73. [84]Grupp SA, “ Chimeric antigen receptor-modified T cells for acute lymphoid leukemia,” N. Engl. J. Med, vol. 368, no. 16, pp. 1509– 1518, 4. 2013, doi: 10.1056/NEJMoa1215134. 23527958 PMC4058440 · DOI · Paper page
  74. [85]Fitzgerald JC, “ Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia,” Crit. Care Med, vol. 45, no. 2, pp. e124– e131, 2. 2017, doi: 10.1097/CCM.0000000000002053. 27632680 PMC5452983 · DOI
  75. [86]Frey NV, “ Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells,” Blood, vol. 124, no. 21, pp. 2296– 2296, 12. 2014, doi: 10.1182/blood.V124.21.2296.2296. · DOI
  76. [87]Teachey DT, “ Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy,” Blood, vol. 121, no. 26, pp. 5154– 5157, 6. 2013, doi: 10.1182/blood-2013-02-485623. 23678006 PMC4123427 · DOI · Paper page
  77. [88]Turtle CJ, “ Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib,” JCO, vol. 35, no. 26, pp. 3010– 3020, 9. 2017, doi: 10.1200/JCO.2017.72.8519. PMC5590803 28715249 · DOI
  78. [91]Rosenberg SA, “ Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer,” N Engl J Med, vol. 313, no. 23, pp. 1485– 1492, 12. 1985, doi: 10.1056/NEJM198512053132327. 3903508 · DOI
  79. [92]Schechter D and Nagler A, “ Recombinant interleukin-2 and recombinant interferon α immunotherapy cardiovascular toxicity,” American Heart Journal, vol. 123, no. 6, pp. 1736– 1739, 6. 1992, doi: 10.1016/0002-8703(92)90856-Q. 1595573 · DOI
  80. [93]Mann H, Ward JH, and Samlowski WE, “ Vascular leak syndrome associated with interleukin-2: chest radiographic manifestations.,” Radiology, vol. 176, no. 1, pp. 191– 194, 7. 1990, doi: 10.1148/radiology.176.1.2353090. 2353090 · DOI
  81. [94]Ognibene FP, “ Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock,” Chest, vol. 94, no. 4, pp. 750– 754, 10. 1988, doi: 10.1378/chest.94.4.750. 3262487 · DOI
  82. [95]Rosenberg SA, “ Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2,” JAMA, vol. 271, no. 12, p. 907, 3. 1994, doi: 10.1001/jama.1994.03510360033032. 8120958 · DOI
  83. [96]White RL, “ Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma,” Cancer, vol. 74, no. 12, pp. 3212– 3222, 12. 1994, doi: 10.1002/1097-0142(19941215)74:12<3212::aid-cncr2820741221>3.0.co;2-i. 7982185 · DOI
  84. [97]Kragel AH, Travis WD, Steis RG, Rosenberg SA, and Roberts WC, “ Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer,” Cancer, vol. 66, no. 7, pp. 1513– 1516, 10. 1990, doi: 10.1002/1097-0142(19901001)66:7<1513::aid-cncr2820660713>3.0.co;2-x. 2208002 · DOI
  85. [99]Sonnenblick M, Rosenmann D, and Rosin A, “ Reversible cardiomyopathy induced by interferon,” BMJ, vol. 300, no. 6733, pp. 1174– 1175, 5 1990, doi: 10.1136/bmj.300.6733.1174. 2346805 PMC1662916 · DOI
  86. [100]Teragawa H, Hondo T, Amano H, Hino F, and Ohbayashi M, “ Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C,” Jpn Heart J, vol. 37, no. 6, pp. 905– 915, 11. 1996, doi: 10.1536/ihj.37.905. 9057685 · DOI
  87. [101]Crown J, “ A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer,” Blood, vol. 78, no. 6, pp. 1420– 1427, 9. 1991. 1884014
  88. [102]Conlon KC, “ Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer,” JCO, vol. 33, no. 1, pp. 74– 82, 1. 2015, doi: 10.1200/JCO.2014.57.3329. PMC4268254 25403209 · DOI
  89. [103]Zhang L, “ Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma,” Clin. Cancer Res, vol. 21, no. 10, pp. 2278– 2288, 5 2015, doi: 10.1158/1078-0432.CCR-14-2085. 25695689 PMC4433819 · DOI
  90. [104]Hegewisch S, “ TNF-induced cardiomyopathy,” The Lancet, vol. 335, no. 8684, pp. 294– 295, 2. 1990, doi: 10.1016/0140-6736(90)90115-L. 1967751 · DOI
  91. [105]Latini R, “ Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist,” J. Cardiovasc. Pharmacol, vol. 23, no. 1, pp. 1– 6, 1. 1994. 7511719
  92. [106]Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, and Mann DL, “Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD),” J. Am. Coll. Cardiol, vol. 27, no. 5, pp. 1201– 1206, 4. 1996, doi: 10.1016/0735-1097(95)00589-7. 8609343 · DOI · Paper page
  93. [107]Koller-Strametz J, Pacher R, Frey B, Kos T, Woloszczuk W, and Stanek B, “ Circulating tumor necrosis factor-alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neurohumoral variables,” J. Heart Lung Transplant, vol. 17, no. 4, pp. 356– 362, 4. 1998. 9588580
  94. [108]Guo L, Liu M-F, Huang J-N, Li J-M, Jiang J, and Wang J-A, “ Role of interleukin-15 in cardiovascular diseases,” J. Cell. Mol. Med, 5 2020, doi: 10.1111/jcmm.15296. PMC7339208 32406586 · DOI
  95. [109]Allam G, Abdel-Moneim A, and Gaber AM, “ The pleiotropic role of interleukin-17 in atherosclerosis,” Biomed. Pharmacother, vol. 106, pp. 1412– 1418, 10. 2018, doi: 10.1016/j.biopha.2018.07.110. 30119214 · DOI
  96. [110]Paulus WJ, “ Cytokines and heart failure,” Heart Fail Monit, vol. 1, no. 2, pp. 50– 56, 2000. 12634874
  97. [111]Mann DL, “ The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls,” Circ. Res, vol. 108, no. 9, pp. 1133– 1145, 4. 2011, doi: 10.1161/CIRCRESAHA.110.226936. 21527743 PMC3084988 · DOI
  98. [112]Prabhu SD, “ Cytokine-Induced Modulation of Cardiac Function,” Circulation Research, vol. 95, no. 12, pp. 1140– 1153, 12. 2004, doi: 10.1161/01.RES.0000150734.79804.92. 15591236 · DOI
  99. [113]Natanson C, “ Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock.,” The Journal of Experimental Medicine, vol. 169, no. 3, pp. 823– 832, 3. 1989, doi: 10.1084/jem.169.3.823. 2647895 PMC2189288 · DOI
  100. [114]Pagani FD, Baker LS, Hsi C, Knox M, Fink MP, and Visner MS, “ Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs,” J. Clin. Invest, vol. 90, no. 2, pp. 389– 398, 8. 1992, doi: 10.1172/JCI115873. 1644912 PMC443113 · DOI
  101. [115]Bozkurt B, “ Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats,” Circulation, vol. 97, no. 14, pp. 1382– 1391, 4. 1998, doi: 10.1161/01.cir.97.14.1382. 9577950 · DOI · Paper page
  102. [116]Cailleret M, “ N-acetylcysteine prevents the deleterious effect of tumor necrosis factor-(alpha) on calcium transients and contraction in adult rat cardiomyocytes,” Circulation, vol. 109, no. 3, pp. 406– 411, 1. 2004, doi: 10.1161/01.CIR.0000109499.00587.FF. 14732751 · DOI
  103. [117]Kumar A, Thota V, Dee L, Olson J, Uretz E, and Parrillo JE, “ Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum.,” The Journal of Experimental Medicine, vol. 183, no. 3, pp. 949– 958, 3. 1996, doi: 10.1084/jem.183.3.949. 8642298 PMC2192364 · DOI
  104. [118]Franco F, “ Magnetic resonance imaging and invasive evaluation of development of heart failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha,” Circulation, vol. 99, no. 3, pp. 448– 454, 1. 1999, doi: 10.1161/01.cir.99.3.448. 9918534 · DOI
  105. [119]Bryant D, “ Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha,” Circulation, vol. 97, no. 14, pp. 1375– 1381, 4. 1998, doi: 10.1161/01.cir.97.14.1375. 9577949 · DOI
  106. [120]Jarrah AA, “ SDF-1 induces TNF-mediated apoptosis in cardiac myocytes,” Apoptosis, vol. 23, no. 1, pp. 79– 91, 2018, doi: 10.1007/s10495-017-1438-3. 29236198 PMC6019273 · DOI
  107. [121]Krown KA, “ Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death,” J. Clin. Invest, vol. 98, no. 12, pp. 2854– 2865, 12. 1996, doi: 10.1172/JCI119114. 8981934 PMC507753 · DOI
  108. [122]Olivetti G, “ Apoptosis in the Failing Human Heart,” N Engl J Med, vol. 336, no. 16, pp. 1131– 1141, 4. 1997, doi: 10.1056/NEJM199704173361603. 9099657 · DOI · Paper page
  109. [123]Rozanski GJ and Witt RC, “ IL-1 inhibits beta-adrenergic control of cardiac calcium current: role of L-arginine/nitric oxide pathway,” Am. J. Physiol, vol. 267, no. 5 Pt 2, pp. H1753– 1758, 11. 1994, doi: 10.1152/ajpheart.1994.267.5.H1753. 7526712 · DOI
  110. [124]Ferdinandy P, Danial H, Ambrus I, Rothery RA, and Schulz R, “ Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure,” Circ. Res, vol. 87, no. 3, pp. 241– 247, 8. 2000, doi: 10.1161/01.res.87.3.241. 10926876 · DOI
  111. [125]Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, and Simmons RL, “ Negative inotropic effects of cytokines on the heart mediated by nitric oxide,” Science, vol. 257, no. 5068, pp. 387– 389, 7. 1992, doi: 10.1126/science.1631560. 1631560 · DOI
  112. [126]Comini L, Pasini E, Bachetti T, Dreano M, Garotta G, and Ferrari R, “ Acute haemodynamic effects of IL-6 treatment in vivo: involvement of vagus nerve in NO-mediated negative inotropism,” Cytokine, vol. 30, no. 5, pp. 236– 242, 6. 2005, doi: 10.1016/j.cyto.2005.01.009. 15927847 · DOI
  113. [127]Yu X, Kennedy RH, and Liu SJ, “ JAK2/STAT3, not ERK1/2, mediates interleukin-6-induced activation of inducible nitric-oxide synthase and decrease in contractility of adult ventricular myocytes,” J. Biol. Chem, vol. 278, no. 18, pp. 16304– 16309, 5 2003, doi: 10.1074/jbc.M212321200. 12595539 · DOI
  114. [128]Madjid M, Safavi-Naeini P, Solomon SD, and Vardeny O, “ Potential Effects of Coronaviruses on the Cardiovascular System: A Review,” JAMA Cardiol, 3. 2020, doi: 10.1001/jamacardio.2020.1286. 32219363 · DOI
  115. [129]Baldi E, “ Out-of-Hospital Cardiac Arrest during the Covid-19 Outbreak in Italy,” N Engl J Med, vol. 383, no. 5, pp. 496– 498, 7. 2020, doi: 10.1056/NEJMc2010418. 32348640 PMC7204428 · DOI
  116. [130]Guo T, “ Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19),” JAMA cardiology, vol. 5, no. 7, pp. 811– 818, 01 2020, doi: 10.1001/jamacardio.2020.1017. 32219356 PMC7101506 · DOI · Paper page
  117. [131]Li C, “ Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients,” J. Mol. Cell. Cardiol, vol. 147, pp. 74– 87, 8. 2020, doi: 10.1016/j.yjmcc.2020.08.008. 32827510 PMC7438272 · DOI
  118. [132]Inciardi RM, “ Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19),” JAMA Cardiol, 3. 2020, doi: 10.1001/jamacardio.2020.1096. PMC7364333 32219357 · DOI
  119. [134]Puntmann VO, “ Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19),” JAMA Cardiol, 7. 2020, doi: 10.1001/jamacardio.2020.3557. PMC7385689 32730619 · DOI
  120. [135]Zeng J-H, “ First case of COVID-19 complicated with fulminant myocarditis: a case report and insights,” Infection, 4. 2020, doi: 10.1007/s15010-020-01424-5. PMC7146072 32277408 · DOI
  121. [136]Hu H, Ma F, Wei X, and Fang Y, “ Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin,” European Heart Journal, p. ehaa190, 3. 2020, doi: 10.1093/eurheartj/ehaa190. PMC7184348 32176300 · DOI
  122. [137]Topol EJ, “ COVID-19 can affect the heart,” Science, 9. 2020, doi: 10.1126/science.abe2813. 32967937 · DOI
  123. [139]Huang C, “ Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China,” The Lancet, vol. 395, no. 10223, pp. 497– 506, 2. 2020, doi: 10.1016/S0140-6736(20)30183-5. PMC7159299 31986264 · DOI · Paper page
  124. [142]Yuan J, “ The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients,” Inflamm. Res, 3. 2020, doi: 10.1007/s00011-020-01342-0. PMC7103893 32227274 · DOI
  125. [143]Grifoni E, “ Interleukin-6 as prognosticator in patients with COVID-19,” Journal of Infection, vol. 81, no. 3, pp. 452– 482, 9. 2020, doi: 10.1016/j.jinf.2020.06.008. PMC7278637 32526326 · DOI
  126. [144]Toniati P, “ Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy,” Autoimmun Rev, p. 102568, 5 2020, doi: 10.1016/j.autrev.2020.102568. 32376398 PMC7252115 · DOI
  127. [145]Xu X, “ Effective treatment of severe COVID-19 patients with tocilizumab,” Proc. Natl. Acad. Sci. U.S.A, vol. 117, no. 20, pp. 10970– 10975, 19 2020, doi: 10.1073/pnas.2005615117. 32350134 PMC7245089 · DOI
  128. [148]Deza Leon MP, “ COVID-19–Associated Pediatric Multisystem Inflammatory Syndrome,” Journal of the Pediatric Infectious Diseases Society, p. piaa061, 5 2020, doi: 10.1093/jpids/piaa061. PMC7313914 32441749 · DOI
  129. [149]Ahmed M, “ Multisystem inflammatory syndrome in children: A systematic review,” EClinicalMedicine, p. 100527, 9. 2020, doi: 10.1016/j.eclinm.2020.100527. 32923992 PMC7473262 · DOI
  130. [150]Shulman ST, “ Pediatric COVID-associated Multi-system Inflammatory Syndrome (PMIS),” J Pediatric Infect Dis Soc, 5 2020, doi: 10.1093/jpids/piaa062. PMC7313948 32441751 · DOI
  131. [151]Belhadjer Z, “ Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic,” Circulation, 5 2020, doi: 10.1161/CIRCULATIONAHA.120.048360. 32418446 · DOI
  132. [152]Spaapen RM, “ Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature,” J. Immunol, vol. 193, no. 8, pp. 4254– 4260, 10. 2014, doi: 10.4049/jimmunol.1401109. 25217157 · DOI
  133. [153]Porter D, Frey N, Wood PA, Weng Y, and Grupp SA, “ Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel,” J Hematol Oncol, vol. 11, no. 1, p. 35, 02 2018, doi: 10.1186/s13045-018-0571-y. 29895316 PMC5998449 · DOI
  134. [154]Lee DW, “ Current concepts in the diagnosis and management of cytokine release syndrome,” Blood, vol. 124, no. 2, pp. 188– 195, 7. 2014, doi: 10.1182/blood-2014-05-552729. 24876563 PMC4093680 · DOI · Paper page
  135. [155]Porter DL, “ Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia,” Sci Transl Med, vol. 7, no. 303, p. 303ra139, 9. 2015, doi: 10.1126/scitranslmed.aac5415. PMC5909068 26333935 · DOI · Paper page
  136. [156]Lee DW, “ ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells,” Biol. Blood Marrow Transplant, vol. 25, no. 4, pp. 625– 638, 2019, doi: 10.1016/j.bbmt.2018.12.758. 30592986 PMC12180426 · DOI · Paper page
  137. [157]Brudno JN and Kochenderfer JN, “ Toxicities of chimeric antigen receptor T cells: recognition and management,” Blood, vol. 127, no. 26, pp. 3321– 3330, 30 2016, doi: 10.1182/blood-2016-04-703751. 27207799 PMC4929924 · DOI

Cited by

Sorted by citations

Authors
Baik, A. H., Oluwole, O. O., Johnson, D. B., Shah, N., Salem, J.-E., Tsai, K. K., & Moslehi, J. J.
Affiliations
  • University of California, San Francisco (US)
  • Vanderbilt University Medical Center (US)
  • Sorbonne Université (FR)
ORCID
Venue
Circulation Research
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2021-05-28
Volume
128
Issue
11
Pages
1780-1801
ISSN
  • 0009-7330 (ISSN-L)
  • 1524-4571
DOI
10.1161/circresaha.120.315894
PMC
PMC8159878
OpenAlex
W3157918517
Cited by
138
References
22
Citations by year
2026: 33 · 2025: 28 · 2024: 36 · 2023: 18 · 2022: 20 · 2021: 3
FWCI
3.76
Type
journal article
Language
en
Open access
Locations
  • Circulation Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • HAL (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • HHS National Institutes of Health (T32 HL007731-28, R01HL41446 and)
  • HHS | National Institutes of Health (R01HL155990)
  • BMS
  • Incyte
  • Janssen
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Keywords
cardio-oncology, immune checkpoint inhibitors, bispecific T-cell engagers, CAR T-cell therapy, cytokine release syndrome, T cell activation, immune activation, cancer immunotherapy
MeSH terms
Receptors, Chimeric Antigen, Cytokine Release Syndrome, Immune Checkpoint Inhibitors, Animals, Cardiovascular Diseases, Disease Models, Animal, Dogs, Humans, Immunotherapy, Lymphocyte Activation, Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive, Antibodies, Bispecific, Mice, Rats, Cardiotoxicity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review